Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
about
Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndromeThe clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot studyFunctional GI disorders: from animal models to drug development.Novel therapeutic agents in neurogastroenterology: advances in the past year.Serotonin: a mediator of the brain-gut connection.Treatment of irritable bowel syndrome: a review of randomised controlled trials.Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.Serotonergic modulating drugs for functional gastrointestinal diseases.Acupuncture for visceral pain: neural substrates and potential mechanisms.Role of serotonin in the pathophysiology of the irritable bowel syndrome.The role of experimental models in developing new treatments for irritable bowel syndrome.Novel therapies in the treatment of irritable bowel syndrome.Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoeaThe 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndromePharmacology of serotonin: what a clinician should know.Update in the pharmaceutical therapy of the irritable bowel syndrome.Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trialPharmacologic Agents for Chronic Diarrhea.Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.Effects of ramosetron on gastrointestinal transit of Guinea pigMechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders.Effects of 5-HT2B, 5-HT3 and 5-HT4 receptor antagonists on gastrointestinal motor activity in dogsReview article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents.Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome.By what mechanism does ondansetron inhibit colonic migrating motor complexes: does it require endogenous serotonin in the gut wall?Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.5-Hydroxytryptamine and functional bowel disorders.Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity.Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome.Effect of granisetron on radiation-induced alterations of colonic motility and fluid absorption in rats.New and emerging treatments for irritable bowel syndrome and functional dyspepsia.Mast cells: a possible link between psychological stress, enteric infection, food allergy and gut hypersensitivity in the irritable bowel syndrome.Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.Existing and emerging therapies for managing constipation and diarrhea.Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
P2860
Q26862565-5A75888C-3021-44CF-BC44-2DDAD0589D0BQ27024521-1B7CCA83-88FF-4015-BED6-55F9D4DF2B25Q28379389-23DFC62C-FDBB-4E24-960C-9B3D91B0DF8CQ30433078-CADC77DA-6F71-4CFF-8359-1DD612FA6B5FQ33934623-B1CF0EA4-3375-4D26-8F7E-D2BAF9535AEEQ34070408-3B32D06C-994A-47DB-8581-C0631DF37D96Q34130605-8D80B400-11AF-452E-A234-0FC0351DCFE3Q34378949-B0D295DF-D501-4AB2-9BB1-26CBE079ECE8Q34722737-32FD245E-ACC8-4318-84CB-F45AFCE8841BQ34966570-56C30848-28C7-4D92-A2D0-2A8EF6E6D34DQ35047066-C6C2FB24-2C35-414B-878A-4278363E56D0Q35071310-AA36CE71-BAC9-45CB-93FA-F067D85989EFQ35094684-FD1F5745-3D98-4304-8E3E-94E3D27B4C7CQ35350975-18EF759D-564A-47F0-AFD0-8CB56AC7A84CQ35359830-81434CDC-27FB-4230-AFC3-B84DF79D4714Q35362266-70D5B6AE-F8BF-4D4E-8E6A-9761BC7BB24BQ35596862-41C96C61-5061-4D0C-A8F7-66C69C5CC97EQ35782673-4B39D677-451F-4E1E-82C1-A518496A6858Q36055161-A622AF1F-8C47-4D47-A1D8-D41094EE81B8Q36271715-679342E0-2D37-407B-9579-BC9A299F923DQ36536707-8F1DDE50-3F73-4164-9A06-D37B18AEFC7AQ36542674-02D5B9DC-77A2-4632-A989-7EEC38DC7913Q36874388-861F24B5-E0C1-45D5-8365-01564F01A22BQ37241590-E4F19B91-3849-4445-AB9A-44396DE545E1Q37506609-BC627EAC-F7E3-48F2-8E70-68B7D8EDA048Q38178543-12847300-6549-4215-B9FC-4DAABC2ED513Q38990851-77CF8BD9-0CCF-4057-A6DE-E193E317EA6EQ39228931-7A898588-1AB1-4536-A1FC-F57CB9AC6887Q39436676-5569926A-EA4B-4CBE-A513-5C53C1DC173AQ41262792-4712CC9F-5981-4C07-B28B-DDB29CF92F4DQ42114573-338141A7-CB38-4608-9D59-BBEDD7E0A763Q43341045-C8746DB7-047F-4031-91BB-37DADB5A2B93Q43904309-12F5B069-6877-4225-B351-389C8DD3F130Q46576618-D9CBAA47-9AFC-49DC-8361-5F20F8E6A246Q48338957-E905D9CF-3445-45AB-854A-52182A112568Q48389586-C9B3EA5A-4663-4B52-BE1E-2157048008EEQ49677641-9A004733-E510-4087-B4C7-1FB9C71DB390Q53755018-D289FDD5-4D1C-4397-BCD4-BC0C76DCDF44
P2860
Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Selective 5-hydroxytryptamine ...... bowel syndrome: a pilot study.
@en
Selective 5-hydroxytryptamine ...... bowel syndrome: a pilot study.
@nl
type
label
Selective 5-hydroxytryptamine ...... bowel syndrome: a pilot study.
@en
Selective 5-hydroxytryptamine ...... bowel syndrome: a pilot study.
@nl
prefLabel
Selective 5-hydroxytryptamine ...... bowel syndrome: a pilot study.
@en
Selective 5-hydroxytryptamine ...... bowel syndrome: a pilot study.
@nl
P2093
P1476
Selective 5-hydroxytryptamine ...... bowel syndrome: a pilot study.
@en
P2093
C J Steadman
N J Talley
S F Phillips
P304
P356
10.1016/S0025-6196(12)60797-6
P407
P577
1992-08-01T00:00:00Z